Chloralose Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is crystalline α-chloralose (CAS 15879-93-3; molecular formula C₈H₁₁Cl₃O₆; relative molecular mass 309.53 g/mol) supplied for further pharmaceutical manufacture, not for direct administration. The synthesis route is based on acid-catalyzed condensation of chloral with glucose, followed by recrystallization to control β-chloralose, the principal process-related stereoisomer. Available release models include an unmicronized grade for dry powder blending, a micronized grade with controlled particle-size distribution for tablet and capsule content uniformity, and a low-dust premix grade for medicated feed production. Packaging is supplied in 1 kg, 5 kg, and 25 kg double LDPE liners inside aluminium foil laminate bags under nitrogen. In veterinary medicine, the API is formulated into tablets, injectable solutions, capsules, powders, granules, premixes, and oral solutions for sedation, immobilization, or general anesthesia in birds, rodents, suids, and other species under professional supervision. These dosage forms require separate particle-size, dissolution, and stability controls because α-chloralose is only sparingly soluble in cold water, requiring approximately 30–100 parts of water per part of solute at 20 °C, and exhibits a limited analgesic ceiling.

What release criteria govern the Veterinary Grade API before tableting or sterile filtration?

Release testing is performed under GMP using pharmacopoeial and ICH reference methods. Identification is by infrared absorption spectrophotometry against an α-chloralose reference standard. Assay by high-performance liquid chromatography with ultraviolet detection requires 98.0–102.0% on the dried basis. Related substances limits are applied to control β-chloralose, chloral hydrate, and glucose-derived impurities; β-chloralose is limited to ≤0.3% because higher levels alter dissolution and reduce expected activity on a weight basis. Residual solvents are controlled according to ICH Q3C(R8); methanol and dichloromethane are the most commonly reported process solvents and are limited to ≤3000 ppm and ≤600 ppm, respectively. The following release specification matrix applies to a typical veterinary-grade lot.

Microbial quality applies to the non-sterile API. If the API is used to manufacture sterile injectable solutions, the finished product must meet sterility according to Ph. Eur. 2.6.1 and bacterial endotoxin limits according to Ph. Eur. 2.6.14; compliance cannot be inferred from API release data alone. The micronized grade is tested by laser diffraction according to Ph. Eur. 2.9.31, and batch-to-batch trend data for D90 should be reviewed when a downstream process is sensitive to surface-area changes.

Regulatory submission support for the API includes drug master file documentation of the synthesis route, critical process parameters, and validation data. The condensation and recrystallization stages are the main controls for β-chloralose and residual chloral; milling is the main control for particle size. Process analytical technology can be applied to monitor crystallization, but published data for this specific API configuration is limited. Manufacturers qualifying a micronized grade should request batch-to-batch particle-size trend data, because milling chamber pressure, feed rate, and classifier speed interact to shift D90.

Solid-dosage processing begins with a moisture check because ambient relative humidity above 60% produces measurable water uptake and shifts loss-on-drying before blending. Direct-compression tablet formulations commonly contain 10% w/w API, 88% w/w lactose monohydrate or microcrystalline cellulose, 1% w/w crospovidone, and 1% w/w magnesium stearate; blending in a V-blender at 25 rpm for 15 min after lubricant addition produces acceptable content uniformity only if the API is pre-sieved through a 500 µm screen. Tablet hardness values of 6–10 kp typically achieve disintegration below 15 min in purified water at 37 °C when crospovidone is present at 2–5 wt%; tablets hardened above 12 kp may fail disintegration if wet granulation produced dense granules. Wet granulation with cold water as the sole granulation fluid can delay dissolution because α-chloralose remains largely undissolved and forms hard granules. Hydroalcoholic granulation using 60–70% ethanol at 50–60 °C partially dissolves the API and improves intragranular distribution; tray drying to a final moisture of ≤3.5% w/w prevents sticking on rotary presses operated above 25 kN compression force. Capsule filling shows segregation when filler bulk density differs from API bulk density by more than 0.2 g/mL; inclusion of 0.5% w/w colloidal silicon dioxide and geometric dilution before final blending reduces this risk. On dosator-type capsule machines, fill compaction forces above 300 N can densify the blend and prolong dissolution.

If injectable solutions are manufactured by heat-assisted dissolution

Injectable preparations are typically prepared at 10–20 mg/mL in sterile water for injection or normal saline. The API is added with continuous stirring to heated vehicle at 50–65 °C; dissolution equipment should avoid high-shear mixing because surface foaming entrains air and may accelerate oxidation. After complete dissolution, the solution is cooled to 20–25 °C and sterile-filtered through a 0.22 µm PVDF or polyethersulfone membrane; a 0.45 µm clarifying filter is not a substitute for sterilizing-grade filtration. Aqueous pH should remain between 4.0 and 7.0; formulations above 7.5 show accelerated degradation of the trichloroethylidene acetal system, while pH below 3.0 increases hydrolysis. Solutions stored at 2–8 °C may precipitate and require warming to 35 °C with inspection for redissolution before use. Terminal steam sterilization is not assigned as a routine method because chloralose solutions are heat-sensitive; aseptic filtration is the preferred sterile-manufacturing route. If polysorbate 80 is added for solubility or viscosity, filter throughput and membrane extractables should be qualified because surfactant interaction can reduce effective pore-size retention.

Powders, granules, and medicated premixes require low-dust handling because α-chloralose is a central depressant and operator exposure must be minimized with a downflow booth meeting ISO 14644-1 class 8 or better. Premix dilution is performed with geometric blending: the API is first diluted 1:10 with lactose monohydrate or wheat-middling carrier in a tumble blender, then incorporated at 10–20 rpm for 15–25 min. Direct addition of active above 2% w/w without geometric dilution can create assay hotspots and failure of blend uniformity. Pelleted premixes should be produced with die temperatures below 60 °C because higher temperatures increase related substances with residence time; roller compaction and extrusion-spheronization require dry-binding agents such as microcrystalline cellulose at 10–20% w/w. Blend homogeneity is tested by taking 10 samples across the discharge stream; acceptance is 90–110% of label claim with relative standard deviation ≤5.0% for most veterinary premix applications. Powders for oral solution are likewise affected by cold-water solubility; reconstitution in water at 40–50 °C reduces undissolved crystals, but the resulting solution should be cooled before administration.

Comparative pharmacological and formulation profile against chloral hydrate and dissociative anesthetics

Chloralose Veterinary Grade API differs from chloral hydrate, tribromoethanol, α₂-adrenergic sedatives, and dissociative anesthetics in regulatory status, formulation chemistry, and clinical limitations. Chloralose has no established specific reversal agent; α₂-adrenergic sedatives such as medetomidine and xylazine are reversed by atipamezole, whereas ketamine or tiletamine–zolazepam have no direct reversal but shorter recovery in many species. Chloralose is generally used where preservation of cardiovascular reflexes and prolonged sedation are required; its analgesic ceiling is low, and procedures involving substantial pain require adjunctive local or systemic analgesia. Unlike ketamine hydrochloride, which is freely water-soluble, chloralose requires heat-assisted dissolution or hydroalcoholic granulation for many dosage forms. Technical-grade chloralose is not manufactured under GMP and is not tested for β-chloralose, residual solvents, microbial quality, or particle-size distribution; it should not be substituted for the veterinary API in pharmaceutical preparation. Chloral hydrate differs by being a deliquescent solid requiring moisture-protective packaging, while tribromoethanol is often supplied as a hygroscopic solid or solution that degrades rapidly in aqueous media.

Storage and handling boundaries are defined by the chemical stability of the chlorinated acetal ring. The API should be stored in well-closed containers at 15–25 °C, protected from light, and pre-dried before weighing when ambient relative humidity exceeds 60%. Incompatibilities include strong bases, strong oxidizing agents, and alkaline excipients that raise microenvironmental pH above 7.5; such conditions accelerate decomposition to chloral hydrate and glucose-derived fragments. Use in food-producing animals is not supported in many jurisdictions because residue depletion data for chloralose are limited. Published species-specific pharmacokinetic data for chloralose in all target species are incomplete; manufacturers should establish dose uniformity, dissolution, and stability under the intended route of administration rather than relying on data from non-veterinary material.